prodchem
Aug 24, 2026
Revvity's acquisition of Toronto-based Advanced Chemistry Development Inc. (ACD/Labs) strengthens its position in scientific software and expands the geographic reach of its life sciences technology business. Revvity completed the acquisition in the first quarter of 2026 for $72 million in cash, with up to $8 million in contingent consideration tied to revenue targets through 2028. ACD/Labs has approximately 200 employees and is now part of Revvity's Life Sciences segment.
ACD/Labs develops scientific software supporting analytical characterization and molecular design across pharmaceutical and materials-science markets. Its portfolio includes the Spectrus platform for spectral analysis, Percepta for AI-driven molecular property and ADMET prediction, and software supporting pharmaceutical chemistry, experimentation, manufacturing and analytical data management.
The acquisition therefore expands Revvity Signals beyond data management into a broader set of scientific workflows. By combining the two portfolios, Revvity aims to connect molecular design and analytical data with development, scale-up and manufacturing activities.
ACD/Labs is headquartered in Toronto, Canada, giving Revvity a stronger Canadian base for scientific software development while adding a team with more than three decades of experience in chemical informatics. ACD/Labs has served customers across pharmaceuticals, chemicals, food and beverage, environmental science, agrochemicals and other research-intensive industries.
This cross-border expansion is significant because scientific software increasingly requires specialized expertise in chemistry, data science and laboratory workflows. Rather than building these capabilities internally, Revvity gains an established technology portfolio and an experienced workforce through the acquisition.
ACD/Labs' technologies are particularly relevant to pharmaceutical research. Its software helps scientists characterize molecules, interpret analytical information, predict molecular properties and manage data across development workflows.
That gives Revvity an opportunity to capture more value from the pharmaceutical R&D technology chain. The combined platform can potentially support customers from early discovery through development and manufacturing, increasing the number of workflows in which Revvity's software can be embedded.
Revvity's management has indicated that the integration is progressing faster than anticipated. During its second-quarter 2026 earnings discussion, the company said it was seeing early momentum in both synergy realization and interoperability between ACD/Labs products and its existing offerings.
Management has also described ACD/Labs as a strategic "tuck-in" acquisition for the Signals portfolio, citing both revenue and cost synergies as potential benefits.
This is important because the relatively modest purchase price means Revvity does not need transformational revenue growth from ACD/Labs for the acquisition to become strategically meaningful. Successful product integration and cross-selling could instead provide incremental value across the existing Signals customer base.
The acquisition also fits Revvity's broader push toward AI-enabled scientific workflows. ACD/Labs describes its technologies as providing harmonized, AI-ready analytical, structural and molecular information, while Revvity has continued expanding the AI capabilities of its Signals platform.
In July 2026, Revvity announced an integration between Signals and Anthropic's Claude through a Model Context Protocol connector, allowing scientists to interact with connected R&D knowledge through Claude.
The combination of chemical intelligence, structured scientific data and AI tools could become increasingly important as pharmaceutical companies seek to automate research workflows and extract more value from existing experimental data.
The ACD/Labs transaction highlights a broader trend in the life sciences technology market: established scientific-software companies are increasingly expanding through acquisitions to combine specialized datasets, domain expertise and AI capabilities.
For Revvity, the Toronto acquisition adds approximately 200 specialists and a mature portfolio of chemistry-focused software without requiring the company to build those capabilities from scratch. It also broadens the potential customer base across pharmaceutical and materials-science organizations.
Revvity's acquisition of ACD/Labs is relatively small financially, but strategically significant. The transaction expands Revvity Signals' capabilities in chemical informatics, strengthens its Canadian technology footprint and provides additional tools for pharmaceutical and materials-science R&D.
The key opportunity now lies in integration. If Revvity can successfully connect ACD/Labs' analytical and molecular-design technologies with its existing Signals ecosystem, the acquisition could help create a more comprehensive platform spanning discovery, analytical characterization, development, scale-up and manufacturing. That would strengthen Revvity's position in the increasingly competitive market for digital life sciences and scientific R&D software.
Featured Product
Found this useful?
Continue Reading
Chemours has pushed through multiple titanium dioxide price increases in 2026 even as it commits to major environmental compliance spending following its EPA settlement. Buyers should understand which cost pressures are actually driving the pricing.
Orion's second quarter results show premium carbon black demand holding strong across Western markets while Asian conditions stay soft. The divergence carries real implications for how buyers plan sourcing and pricing across regions.
